Dioxoindolinonă - a new autohton product with antidepressive activity

Abstract

Introduction. According of American Psychiatric Association,mental health is defined by the simultaneous success in work, love and the ability to resolve with maturity and flexibility the conflict between instinct, consciousness, close persons and reality.There is no universal definition.However, neuropsychiatric disorders are the third cause of disability in Europe and represent 15.2%, after cardiovascular disease 26.6% and malignant neoplasms (cancers) 15.4%.The most common mental illnesses are anxiety, depression and dementia.It is estimated that by 2020 depression will become the second leading cause of disability worldwide, after cardiovascular diseases. Aim of the study. In this study we have proposed as the objective the recipe of the medical scientific literature of the contemporary therapy of depressive states. Materials and methods. The bibliographic and informative sources published in recent years, published both internationally and in the Republic of Moldova, have been used as study materials. Results. Scientific dates demonstrate that treatment of depressive states includes several groups of preparations: selective serotonin reuptake inhibitors (SSRIs),noradrenaline and dopamine reuptake inhibitors (IRND),selective serotonin reuptake enhancers (SSRIs),noradrenergic and serotoninergic antidepressants,serotonin and noradrenaline reuptake inhibitors (IRSN), monoamine oxidase inhibitors (MAOIs),tranquilizing benzodiazepines and nonbenzodiazepine. Of the classes of organic substances with MAO inhibitors are involved and derivatives of 2-indolinone and 2,3-indolinedione.In this context, a new autohtone compound of the isatine group is investigated, with pronounced antidepressant and sedative-tranquilizing activity–1'-(2-oxo-propyl)-spiro[[1,3]dioxolane-2',3'-indolin]-2'-one with the common name "DIOXOINDOLINONE" synthesized in the Organic Synthesis and Biopharma- ceutical Laboratory of the Institute of Chemistry. Conclusions. Although there are already a large number of antidepressant drugs in the pharmaceutical market, the development of new structures remains in the topicality.